Efficacy and Safety of Azacitidine in Patients With RUNX1::RUNX1T1 Measurable Residual Disease-Positive Acute Myeloid Leukemia After Consolidation Therapy Who Did Not Undergo Allogeneic Hematopoietic Stem-Cell Transplantation

Clinical Lymphoma, Myeloma & Leukemia · Elsevier

Аннотация

Publication date: November 2026 Source: Clinical Lymphoma Myeloma and Leukemia, Volume 26, Issue 11 Author(s): Huazhou Shi, Dapeng Peng, Nannan Qi, Yan Wang, Zhiyun Niu, Jingyu Zhang

Читать у издателя →

Похожие статьи